CardioExchange welcomes Arthur Moss, Professor of Medicine at the University of Rochester School of Medicine and lead investigator of the MADIT-CRT trial, to discuss his New England Journal of Medicine editorial on the RAFT trial, in which patients with mild-to-moderate HF were randomized to receive either an ICD alone or ICD plus CRT. It seems…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

The FDA has expanded the indication for CRT-D devices made by Boston Scientific. Previously, the devices had been approved only in NYHA Class III and IV patients. The expanded indication now includes Class I and II patients who have left bundle branch block. The expanded indication is based on data from the MADIT-CRT trial. “This…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.